Linked Life Data

6431198

Source:http://linkedlifedata.com/resource/pubmed/id/6431198

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1984-8-29
pubmed:abstractText
Monoclonal antibodies that define HLA-DR antigen bind to a variety of human tumors, such as Burkitt lymphoma and melanoma cells grown in vitro and with the spent medium of these cultures. Two radioimmunoassays have been developed to detect HLA-DR antigen circulating in human sera. The inhibition assay is based on the inhibition of binding of monoclonal antibodies against HLA-DR to the target preparation; the double-determinant assay traces antigen bound by a solid-phase monoclonal antibody by the use of a second 125I-labeled antibody. Twenty-six of 39 sera from patients with acute lymphoblastoid leukemia, 2 of 29 sera from patients with acute myeloid leukemia, and 5 of 31 sera from patients with advanced metastatic melanoma showed increased levels of HLA-DR antigen, whereas none of 28 sera from patients with other malignancies had increased levels of HLA-DR antigen, and only 2 of 155 sera from healthy donors bound monoclonal antibodies to HLA-DR at detectable levels. The detection of circulating HLA-DR antigen in sera of cancer patients may be useful in monitoring patients with certain malignancies.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0145-2126
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
323-34
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Increased levels of circulating HLA-DR antigen in sera of patients with acute lymphoblastoid leukemia.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't